Millennium claims to have an edge over Big Pharma and big biotechs: an evolved biology-driven approach to discovery and development derived from its roots in genomics, and a corporate culture based on integrating outside technologies that minimizes the Not-Invented-Here syndrome. Skeptics point to the fact that of the hundreds of targets it delivered to partners, none has resulted in a clinical candidate. Nonetheless, Millennium believes it now has a critical mass of knowledge about biological pathways that it can use for shrewd in-licensing and to choose those internal targets from which it will develop small-molecule drugs. But whether R&D proves to be a fertile source of internally discovered compounds or a sophisticated adjunct for licensing and development, Millennium's real challenge is to build a commercial organization and prioritize programs and capacity as it redirects its spending downstream.
by Mark L. Ratner
A year ago, in anticipation of the presentation of Phase II data and a priority review by the Food and...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
A look at Novo Nordisk, Eli Lilly and other companies' late-stage clinical studies of GLP-1 drugs in indications ranging from neurodegeneration to oncology, and alcoholic liver disease to autoimmune conditions.
Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.
Advanced AI is revolutionizing sales enablement by addressing training gaps and performance challenges. Used correctly, it can help to bridge the sales-marketing divide, accelerate ramp-up times and provide managers with data-driven insights.
Annual survey of patients and professionals shows how attitudes to health system transformation are evolving and what stakeholders are demanding as acceptance of AI tools accelerates.
BioWales in London 2025 showcased the efforts healthtech innovators are making to meet investors on their own turf, illustrating changing attitudes and evolving needs.
Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.